Mesto ingibitorov angiotenzinprevrashchayushchego fermenta v profilaktike i lechenii serdechnososudistykh zabolevaniy


Cite item

Full Text

Abstract

Ренин-ангиотензиновая система играет важную роль в развитии сердечно-сосудистых заболеваний. В последние десятилетия активно изучалось действие ингибиторов ангиотензинпревращающего фермента (ИАПФ) при различных заболеваниях сердца и сосудов. В связи с необходимостью систематизировать данные научных исследований и накопленный опыт практического использования этих препаратов Европейское кардиологическое общество в 2004 г. выпустило документ – соглашение экспертов по применению ИАПФ при сердечно-сосудистых заболеваниях. Основные положения этого документа рассмотрены в настоящей статье.

About the authors

N. A Vaulin

Городская клиническая больница №29, Москва

References

  1. Williams G.H. N Ensl J Med 1988; 319: 1517–25.
  2. Brown N.J, Vaughan D.E. Circulation 1998; 97: 1411–20.
  3. Hoyer J, Schulte K.L, Lenz T. Clin Pharmacokinet 1993; 24: 230–54.
  4. Kostis J.B. Am J Hypertens 1989; 2: 57–64.
  5. Jackson E.K. In: Hardman J.G, Limbird L.E (eds.) The pharmacological basis of therapeutics. 10th Ed. N. Y. 2001; 809–41.
  6. Lonn E.M, Yusuf S, Jha P et al. Circulation 1994; 90: 2056–69.
  7. Zimmerman B.G, Sybertz E.J et al. J Hypertens 1984; 2: 581–92.
  8. Hornig H, Kohler C, Drexler H. Circulation 1997; 95: 1115–8.
  9. Linz W, Wohlfart P, Schoelkens B.A et al. Cardiovasc Res 1999; 43: 549–61.
  10. Dzau V.A. Am J Cardiol 2001; 88: 1–20.
  11. Giannettasio C, Grassi G, Seravalle G et al. Am Heart J 1989; 117: 740–5.
  12. Schmieder R.E, Martus P, Klingbeil A. JAMA 1996; 275: 1507–13.
  13. Thadei S, Virdis A, Ghiadoni L et al. J Hypertens 1998; 16: 447–56.
  14. Hornig B, Landmesser U, Kohler С et al. Circulation 2001; 103: 799–805.
  15. Hornig B, Arakawa N, Drexler H. Eur Heart J 1998; 19 (Suppl. G): G48–53.
  16. Francis G.S, Benedict C, Johnstone D.E et al. Circulation 1990; 82: 1724–9.
  17. Swedberg K, Eneroth P, Kjekshus J et al. Circulation 1990; 82: 1730–6.
  18. Swedberg K. Eur J Heart Fail 2000; 2: 229–33.
  19. Husain A. J Hyperten 1993; 11: 1155–9.
  20. Lee A.F, Mac Fadyen R.J, Struthers A.D. Eur J Heart Fail 1999; 1: 401–6.
  21. Paul M, Ganten D. J Cardiovasc Pharmacol 1992; 19 (Suppl. 5): S51–8.
  22. Schiffrin E, Deng L. Hypertension 1995; 25: 699–703.
  23. Matsuda H, Hayashi K, Arakawa K. J Am Soc Nephrol 1999; 10: 2272–82.
  24. Keane W.F, Shapiro B.E. Am J Cardiol 1990; 65: 49l–53.
  25. Ruggenenti P, Perna A, Gherardi G et al. Lancet 1999; 354: 359–64.
  26. Lewis E.J, Hunsicker L.G, Bain R.P et al. N Engl J Med 1993; 329: 1456–62.
  27. Pitt B. Eur Heart J 1995; 16: 49–54.
  28. Schoelkens B.A, Landgraf W. Can J Physiol Phatmacol 2002; 80: 354–9.
  29. Lonn E.M, Yusuf S, Dzavik V et al. Circulation 2001; 103: 919–25.
  30. Visser L.E, Strieker B.H, van der Velden J et al. J Gin Epidemiol 1995; 48: 851–7.
  31. Charlon V, Dollow S, Fidel J et al. Br J Gin Pharmacol 1995; 39: 125–9.
  32. Israili Z.H, Hall W.D. Ann Intern Med 1992; 117: 234–42.
  33. Ahuja T.S, Freeman D, Mahnken J.D et al. Am J Nephrol 2000; 20: 268–72.
  34. The RALES Investigators. Am J Cardiol 1996; 78: 902–7.
  35. Wynckel A, Ebikili B, Melin J-P et al. Am J Hypertens 1998; 11: 1080–6.
  36. Brown N, Ray W, Snowden M et al. Clin Pharmacol Ther 1996; 60: 8–13.
  37. Sedman A.B, Kershaw D.B, Bunchman Т.Е. Pediatr Nephrol 1995; 9: 382–5.
  38. Oakley C, Child A, lung B et al. Eur Heart J 2003; 24: 761–81.
  39. Maron B.J, Mc Kenna W.J, Danielson G.K et al. Eur Heart J 2003; 25: 1965–91.
  40. Brent R.L, Beckman D.A. Teratology 1991; 43: 543–6.
  41. Remme W.J, Swedberg К et al. Eur Heart J 2001; 22: 1527–60.
  42. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult 2002. Available from: http://www.acc.org.
  43. Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8.
  44. Narang R, Swedberg K, Cleland J.G. Eur Heart J 1996; 17: 120–34.
  45. Northridge D.B, Rose E, Raftery E.D et al. Eur Heart J 1993; 14: 403–9.
  46. Packer M, Poole-WHson P.A, M.D, Armstrong P.W et al. Circulation 1999; 100: 2312–8.
  47. Mc Murray J.J.V, Ostergren J, Swedberg К et al. Lancet 2003; 362: 767–71.
  48. The SOLVD Investigators. N Engl J Med 1992; 327: 685–91.
  49. Van de Verf et al. Eur Heart J 2003; 24: 28–66.
  50. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction American College of Cardiology; September 1999. Available from: www.acc.org.
  51. Fourth International Study of Infarct Survival Collaborative Group. ISIS-IV: a randomised factorial trial assessing early oral captopril. Lancet 1995; 345: 669–85.
  52. Gruppo Italiano per lo Studio della Soprawivenza nell'lnfarto Miocardico. GISSI-3. Lancet 1994; 343: 1115–22.
  53. Chinese Cardiac Study Collaborative group. Oral captopril versus placebo among 13634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study. Lancet 1995; 345: 686–7.
  54. Ambrosioni E, Borghi C, Magnani В. N Engt J Med 1995; 332: 80–5.
  55. Wood D, De Backer G, Faergeman O et al. Eur Heart J 1998; 19: 1434–503.
  56. Chobanian A.V, Bakris G.L, Black H.R et al. JAMA 2003; 289: 2560–72.
  57. De Backer G, Ambrosioni E, Borch-Johnses К et al. Eur Heart J 2003; 24: 1601–10.
  58. Hansson L, Lindholm L, Niskanen L et al. Lancet 1999; 353: 611–6.
  59. Collaborative Group Randomised trial of a perindopril - based blood - pressure - lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
  60. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure - lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355: 1955–64.
  61. Staessen J.A, Wang J.G, Thijs L. Lancet 2001; 358: 1305–15.
  62. Wing L.M, Reid C.M, Ryan P et al. N Engl J Med 2003; 348 (7): 583–92.
  63. Major outcomes in high - risk hypertensive patients randomized to angiotensin - converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 2002; 288: 2981–97.
  64. Sleight P, Yusuf S, Pogue J et al. Lancet 2001; 358: 2130–1.
  65. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Lancet 2003; 362: 782–8.
  66. Priori S.G, Aliot E, Blomstrom-Lundqvist С et al. Eur Heart J 2001; 22: 1374–450.
  67. Priori S.G, Aliot E, Blomstrom-Lundqvist С et al. Eur Heart J 2003; 24: 13–5.

Copyright (c) 2005 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies